- Home
- VRTX vs TD Comparison
VRTX vs TD Comparison
Compare VRTX & TD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- TD
- Stock Information
- Founded
- VRTX 1989
- TD 1855
- Country
- VRTX United States
- TD Canada
- Employees
- VRTX N/A
- TD N/A
- Industry
- VRTX EDP Services
- TD
- Sector
- VRTX Technology
- TD
- Exchange
- VRTX Nasdaq
- TD Nasdaq
- Market Cap
- VRTX 115.6B
- TD 126.6B
- IPO Year
- VRTX 1991
- TD N/A
- Fundamental
- Price
- VRTX $398.10
- TD $74.30
- Analyst Decision
- VRTX Buy
- TD Buy
- Analyst Count
- VRTX 24
- TD 2
- Target Price
- VRTX $496.76
- TD $91.50
- AVG Volume (30 Days)
- VRTX 2.5M
- TD 1.7M
- Earning Date
- VRTX 08-04-2025
- TD 08-28-2025
- Dividend Yield
- VRTX N/A
- TD 4.05%
- EPS Growth
- VRTX N/A
- TD 63.11
- EPS
- VRTX 14.07
- TD 6.97
- Revenue
- VRTX $11,418,800,000.00
- TD $45,024,677,580.00
- Revenue This Year
- VRTX $10.40
- TD $10.95
- Revenue Next Year
- VRTX $10.63
- TD $3.82
- P/E Ratio
- VRTX $28.24
- TD $10.56
- Revenue Growth
- VRTX 10.46
- TD 20.69
- 52 Week Low
- VRTX $362.50
- TD $51.25
- 52 Week High
- VRTX $519.88
- TD $75.58
- Technical
- Relative Strength Index (RSI)
- VRTX 43.02
- TD 51.45
- Support Level
- VRTX $388.93
- TD $73.30
- Resistance Level
- VRTX $400.94
- TD $74.00
- Average True Range (ATR)
- VRTX 12.48
- TD 0.61
- MACD
- VRTX 1.47
- TD -0.06
- Stochastic Oscillator
- VRTX 72.97
- TD 47.55
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 55% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 40% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.